ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

January 3, 2022 GMT

LYON, France--(BUSINESS WIRE)--Jan 3, 2022--

Regulatory News:

MaaT Pharma(EURONEXT: MAAT - the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today that its CEO and co-founder, Hervé Affagard will present the company at the upcoming H.C. Wainwright Bioconnect Virtual Conference held January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 am EST/1:00 pm CET on Monday, January 10, 2022.

ADVERTISEMENT

A replay of the presentation will also be made accessible in the investors’ section of the company’s website at www.maatpharma.com from Friday, January 14, 2022 and for 90 days after the event.

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint ®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.

The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20220103005329/en/

CONTACT: MaaT Pharma

Hervé AFFAGARD

Co-Founder and CEO

Siân Crouzet – COO/CFO

+33 4 28 29 14 00

invest@maat-pharma.comMaaT Pharma

Pauline RICHAUD

PR and Corporate Communications Manager

+33 6 07 55 25 36

prichaud@maat-pharma.comTrophic Communications

Corporate and medical Communications

Jacob VERGHESE or

Gretchen SCHWEITZER

+49 89 23 88 77 31

maat@trophic.eu

KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE NEW YORK

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: MaaT Pharma

Copyright Business Wire 2022.

PUB: 01/03/2022 01:00 PM/DISC: 01/03/2022 01:02 PM

http://www.businesswire.com/news/home/20220103005329/en